meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
drug_id: tremelimumab
generic_name: Tremelimumab
brand_name: Imjudo
drug_class: immune_checkpoint_inhibitor
subclass: anti_CTLA4
molecular_type: monoclonal_antibody
fda_status: approved
approved_indications:
- NSCLC
targets:
- name: CTLA-4
  gene: CTLA4
  type: receptor
  action: antagonist
  selectivity: high
cell_effects:
  CD8_T:
    direct: true
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.08
    - parameter: exhaustion
      direction: decrease
      rate_per_step: 0.04
    functional_effects:
    - action: proliferate
      probability_modifier: 0.15
    - action: attack
      probability_modifier: 0.1
    notes: Primarily enhances T cell priming and expansion
  Tumor:
    direct: false
    state_effects:
    - parameter: apoptosis_susceptibility
      direction: increase
      rate_per_step: 0.03
      condition: nearby_CD8T_count > 1
  Treg:
    direct: true
    state_effects:
    - parameter: suppressive_activity
      direction: decrease
      rate_per_step: 0.06
    functional_effects:
    - action: apoptosis
      probability_modifier: 0.1
    notes: CTLA-4 highly expressed on Tregs; Fc-mediated ADCC depletes Tregs
  Macrophage:
    direct: false
    state_effects:
    - parameter: polarization
      direction: decrease
      rate_per_step: 0.03
    - parameter: phagocytic_activity
      direction: increase
      rate_per_step: 0.04
    notes: Macrophages mediate Treg depletion via ADCC
  NK:
    direct: false
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.03
  B_cell:
    direct: false
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.02
environment_effects:
- field: IFN_gamma
  action: amplify
  magnitude: 0.15
- field: IL2
  action: amplify
  magnitude: 0.1
pharmacokinetics:
  administration: IV
  standard_dose: 75 mg single dose
  onset_steps: 2
  peak_steps: 5
  half_life_steps: 22
  concentration_curve: plateau
  steady_state_fraction: 0.8
dose_response:
  model: hill
  ec50: 0.4
  hill_coefficient: 1.5
  max_effect: 1.0
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 0.3
    notes: Not approved
  Melanoma:
    efficacy_modifier: 0.7
    notes: Inferior to ipilimumab
  NSCLC:
    efficacy_modifier: 0.8
    notes: POSEIDON trial with durvalumab
  CRC-MSI-H:
    efficacy_modifier: 0.6
    notes: Limited data
  CRC-MSS:
    efficacy_modifier: 0.1
    notes: Ineffective
  Ovarian:
    efficacy_modifier: 0.25
    notes: Limited data
resistance:
- mechanism: T cell anergy despite CTLA-4 blockade
  onset_steps: 15
  probability: 0.12
- mechanism: Compensatory PD-1/PD-L1 upregulation
  onset_steps: 10
  probability: 0.15
references:
- description: 'POSEIDON: Durvalumab+Tremelimumab+chemo in NSCLC. Johnson et al. J Clin Oncol 2023'
  pmid: '36327426'
  verified: true
